vTv Therapeutics (VTVT) Income from Continuing Operations (2014 - 2026)
vTv Therapeutics (VTVT) reported Income from Continuing Operations of 24134000.0 for Q1 2026, up 488.19% on a YoY basis from 4103070.39 in Q1 2025, and up 438.11% sequentially from 7138000.0 in Q4 2025.
vTv Therapeutics (VTVT) Income from Continuing Operations (2014 - 2026) Analysis & Trends
vTv Therapeutics (VTVT) has 13 years of Income from Continuing Operations data on file, last reported at 24134000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 488.19% year-over-year to 24134000.0; the trailing twelve-month figure through Mar 2026 stood at 729000.0 (up 96.82% YoY), and the FY2025 full-year result was 31080000.0, down 36.89% from the prior year.
- Income from Continuing Operations climbed to 24134000.0 in Q1 2026, from 7138000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 24134000.0 in Q1 2026 to a low of 10345000.0 in Q3 2025.
- A 5-year average of 4746470.59 and a median of 6090000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations tumbled 386.44% in 2022 and jumped 488.19% in 2026, its largest moves.
- Tracing VTVT's Income from Continuing Operations over 5 years: stood at 6090000.0 in 2022, then gained by 27.08% to 4441000.0 in 2023, then increased by 0.09% to 4437000.0 in 2024, then tumbled by 60.87% to 7138000.0 in 2025, then soared by 438.11% to 24134000.0 in 2026.
- Business Quant data shows VTVT's Income from Continuing Operations at 24134000.0 in Q1 2026, 7138000.0 in Q4 2025, and 10345000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,290.43 Bn | 66,290.15 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 467.97 Bn | 463.18 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.73 Bn | 115.48 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.82 Bn | 62.82 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.00 Bn | 50.82 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.51 Bn | 34.50 Bn | 959.66 Mn | 205.99 Mn |
| 10 | vTv Therapeutics | 19.07 Mn | 19.07 Mn | - | 24.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.13 Mn |
| Dec 31, 2025 | -7.14 Mn |
| Sep 30, 2025 | -10.35 Mn |
| Jun 30, 2025 | -7.38 Mn |
| Mar 31, 2025 | -6.22 Mn |
| Dec 31, 2024 | -4.44 Mn |
| Sep 30, 2024 | -5.84 Mn |
| Jun 30, 2024 | -6.41 Mn |
| Mar 31, 2024 | -6.02 Mn |
| Dec 31, 2023 | -4.44 Mn |
| Sep 30, 2023 | -8.54 Mn |
| Jun 30, 2023 | -7.21 Mn |
| Mar 31, 2023 | -5.77 Mn |
| Dec 31, 2022 | -6.09 Mn |
| Sep 30, 2022 | -5.47 Mn |
| Jun 30, 2022 | -4.09 Mn |
| Mar 31, 2022 | -9.42 Mn |
| Dec 31, 2021 | -9.48 Mn |
| Sep 30, 2021 | -1.47 Mn |
| Jun 30, 2021 | -841,000.00 |